Brickell Biotech announces sale of sofpironium bromide gel to Botanix Pharmaceuticals.
- Brickell Biotech, Inc. announced that it has signed and closed a definitive asset purchase agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, whereby Botanix has acquired the Company’s rights to sofpironium bromide, a retro-metabolically-designed new chemical entity that belongs to a class of medications called anticholinergics.
Sofpironium bromide gel, 15% is a potential best-in-class topical therapy that recently completed a U.S. Phase III pivotal clinical program for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application (“NDA”) to the FDA for sofpironium bromide gel, 15% in mid-2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.